Share This Page
Drug Price Trends for WIXELA
✉ Email this page to a colleague
Average Pharmacy Cost for WIXELA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| WIXELA 100-50 INHUB | 00378-9320-32 | 1.19419 | EACH | 2025-05-21 |
| WIXELA 250-50 INHUB | 00378-9321-32 | 1.42201 | EACH | 2025-05-21 |
| WIXELA 500-50 INHUB | 00378-9322-32 | 1.90288 | EACH | 2025-05-21 |
| WIXELA 100-50 INHUB | 00378-9320-32 | 1.19012 | EACH | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Wixela Inhub
Introduction to Wixela Inhub
Wixela Inhub, developed by Mylan, is the first FDA-approved generic version of GlaxoSmithKline's (GSK) Advair Diskus, a widely used medication for treating asthma and chronic obstructive pulmonary disease (COPD). The launch of Wixela Inhub marked a significant shift in the respiratory drug market, particularly due to its substitutable status and competitive pricing.
Market Impact of Wixela Inhub
Initial Market Penetration
Upon its launch in February 2019, Wixela Inhub quickly gained market share. Within three weeks, it secured 24% of the market, and by the end of April 2019, it held a 28% share, according to data analyzed by RBC Capital Markets[1].
Competitive Pricing
Mylan launched Wixela Inhub at a wholesale acquisition cost 70% less than Advair Diskus and 67% less than GSK's authorized generic version. This pricing strategy was aimed at increasing affordability and reducing out-of-pocket costs for patients and the healthcare system[2].
Financial Impact on GSK
The introduction of Wixela Inhub had a substantial impact on GSK's revenues. The company's shares fell 2% after the earnings release, reflecting the significant decline in Advair sales. GSK executives acknowledged that the full impact of the generic competition had yet to be felt, indicating potential further revenue declines[1].
Price Projections and Market Dynamics
Current Pricing
As of the latest data, the cost for Wixela Inhub inhalation powder varies by strength:
- 100 mcg/50 mcg: Around $104 for a supply of 60 powders
- 250 mcg/50 mcg: Around $142 for a supply of 60 powders
- 500 mcg/50 mcg: Around $164 for a supply of 60 powders[5].
Market Growth and Trends
The global metered dose inhalers (MDIs) and dry powder inhalers (DPIs) market is expected to grow steadily. The MDIs market is forecast to expand at a CAGR of 4.9% from 2023 to 2030, reaching $39.4 billion by the end of the forecast period. This growth is driven by factors such as an aging population, urbanization, and increased environmental pollution, all of which contribute to higher incidence rates of respiratory ailments[3].
Technological Advancements
The market is also witnessing the emergence of innovative technologies, including smart inhalers. These devices are equipped with sensors and connectivity features, allowing for real-time monitoring of inhaler usage and adherence through smartphone apps. Such advancements are expected to improve patient adherence and treatment outcomes, further driving market growth[3].
Generic and Biosimilar Trends
The patent expiration of branded inhaled medications, such as Advair Diskus, has led to the development of generic and biosimilar versions. This trend is expected to continue, with companies focusing on generating low-cost medications to provide cost-effective treatment options for patients with asthma and COPD. The launch of Wixela Inhub is a prime example of this trend, offering significant cost savings compared to the branded version[4].
Patient and Healthcare System Impact
Affordability and Access
The launch of Wixela Inhub has significantly improved affordability for patients. With a price 70% lower than Advair Diskus, it reduces out-of-pocket costs and overall healthcare expenditure. Mylan's patient services, including training and education about the treatment and device, further enhance patient access and adherence[2].
Patient Awareness and Education
Growing patient awareness about the benefits of using DPIs and MDIs is anticipated to drive market growth. However, patients' unawareness about the proper technique of dose administration remains a challenge that needs to be addressed through education and training programs[4].
Key Takeaways
- Market Penetration: Wixela Inhub quickly gained a significant market share upon its launch.
- Pricing Strategy: The generic was launched at a significantly discounted price, 70% less than Advair Diskus.
- Financial Impact: The introduction of Wixela Inhub had a substantial negative impact on GSK's revenues.
- Market Growth: The global MDIs and DPIs market is expected to grow at a CAGR of 4.9% from 2023 to 2030.
- Technological Advancements: Smart inhalers and other innovative technologies are enhancing patient adherence and treatment outcomes.
- Generic and Biosimilar Trends: The development of generic and biosimilar versions of branded medications is expected to continue, driven by patent expirations.
FAQs
What is Wixela Inhub?
Wixela Inhub is the first FDA-approved generic version of GlaxoSmithKline's Advair Diskus, used for treating asthma and COPD.
How did Wixela Inhub impact GSK's revenues?
The launch of Wixela Inhub led to a significant decline in Advair Diskus sales, resulting in a 2% drop in GSK's shares and a substantial impact on the company's revenues.
What is the pricing strategy of Wixela Inhub?
Wixela Inhub was launched at a wholesale acquisition cost 70% less than Advair Diskus and 67% less than GSK's authorized generic version.
What are the key drivers of the MDIs and DPIs market growth?
The market growth is driven by an aging population, urbanization, increased environmental pollution, and the development of innovative technologies such as smart inhalers.
How does Wixela Inhub benefit patients?
Wixela Inhub offers significant cost savings compared to Advair Diskus, improving affordability and access to treatment for patients with asthma and COPD.
What challenges does the market face despite the growth of generics?
Patients' unawareness about the proper technique of dose administration remains a challenge that needs to be addressed through education and training programs.
Sources
- BioPharma Dive: Generic Advair hits GSK revenues hard.
- PR Newswire: Mylan Launches Wixela™ Inhub™ (fluticasone propionate and salmeterol) Inhalation Powder, USP.
- GlobeNewswire: Metered Dose Inhalers Market Forecast a Steady Growth at 4.9% CAGR, Projected to Hit US$39.4 Billion by 2030.
- Fortune Business Insights: Nasal Drug Delivery Market Size, Share, Growth | Forecast.
- Drugs.com: Wixela Inhub Prices, Coupons, Copay Cards & Patient Assistance.
More… ↓
